North America’s medical devices industry saw a drop of 8.2% in overall deal activity during Q4 2019, when compared to the four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 235 deals worth $4.34bn were announced for the region during Q4 2019, against the last four-quarter average of 256 deals.

Of all the deal types, venture financing saw most activity in Q4 2019 with 180, representing a 76.6% share for the region.

In second place was M&A with 44 deals, followed by private equity deals with 11 transactions, respectively capturing an 18.7% and 4.7% share of the overall deal activity for the quarter.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

In terms of value of deals, venture financing was the leading category in North America’s medical devices industry with $1.89bn, while M&A and private equity deals totalled $1.44bn and $1.01bn, respectively.

North America medical devices industry deals in Q4 2019: Top deals

The top five medical devices deals accounted for 43.3% of the overall value during Q4 2019.

The combined value of the top five medical devices deals stood at $1.88bn, against the overall value of $4.34bn recorded for the quarter.

The top five medical devices industry deals of Q4 2019 tracked by GlobalData were:

1) Altaris Capital Partners’s $650m private equity deal with 3M

2) The $525m acquisition of Clinical Innovations by Laborie Medical Technologies

3) Boston Scientific’s $275m acquisition of Channel Medsystems

4) The $221.34m acquisition of AvKare by Amneal Pharmaceuticals

5) Clayton, Dubilier & Rice’s private equity deal with Cynosure for $205m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.